TET 830 modified/T-helper epitope from tetanus toxoid

• UNSPSC Description:

  TET 830 modified/T-helper epitope from tetanus toxoid is a modified T-helper epitope from tetanus toxoid. TET 830 modified/T-helper epitope from tetanus toxoid induces T-cells responses and is used as a helper peptide in vaccinations[1].

• Target Antigen:

  Others

• Type:

  Peptides

• Related Pathways:

  Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/tet-830-modified-t-helper-epitope-from-tetanus-toxoid.html

• Purity:

  99.91

• Solubility:

  H2O : 50 mg/mL (ultrasonic)

• Smiles:

  OC(C=C1)=CC=C1C[C@H](NC([C@H](CCC(N)=O)NC([C@@H](N)C)=O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O)=O)=O

• Molecular Weight:

  1796.07

• References & Citations:

  [1]Slingluff CL Jr, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7(10):3012-3024.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  410527-75-2